Remission Rate by Age and Cytogenetics
| . | Filgrastim . | Placebo . | Total . |
|---|---|---|---|
| Overall | 178/259 (69%) | 177/262 (68%) | 355/521 (68%) |
| Age | |||
| <50 yr | 79/104 (76%) | 82/115 (71%) | 161/219 (74%) |
| ≥50 yr | 99/155 (64%) | 95/147 (65%) | 194/302 (64%) |
| Cytogenetics | |||
| Unfavorable | 51/78 (65%) | 42/75 (56%) | 93/153 (61%) |
| Normal/favorable | 78/104 (75%) | 98/123 (80%) | 176/227 (78%) |
| Not assessed | 49/77 (64%) | 37/64 (58%) | 86/141 (61%) |
| . | Filgrastim . | Placebo . | Total . |
|---|---|---|---|
| Overall | 178/259 (69%) | 177/262 (68%) | 355/521 (68%) |
| Age | |||
| <50 yr | 79/104 (76%) | 82/115 (71%) | 161/219 (74%) |
| ≥50 yr | 99/155 (64%) | 95/147 (65%) | 194/302 (64%) |
| Cytogenetics | |||
| Unfavorable | 51/78 (65%) | 42/75 (56%) | 93/153 (61%) |
| Normal/favorable | 78/104 (75%) | 98/123 (80%) | 176/227 (78%) |
| Not assessed | 49/77 (64%) | 37/64 (58%) | 86/141 (61%) |
Unfavorable: monosomies 5, 7; trisomy 8; 11q(23); complex and multiple abnormalities. Favorable: t(15; 17), t(8; 21), inv(16).